(Q21254640)

Dimensions

1029773929

18 August 2022

Francis M Patafio

series ordinal

2

author given names

Francis M

author last names

Patafio

1 reference

Dimensions

1029773929

18 August 2022

Walter W Rosser

series ordinal

3

author given names

Walter W

author last names

Rosser

1 reference

Dimensions

1029773929

BMC Clinical Pharmacology

18 August 2022

language of work or name

English

0 references

publication date

2011

0 references

28 September 2011

3 references

17 September 2019

2 October 2019

27 September 2020

3 references

17 September 2019

2 October 2019

27 September 2020

11

0 references

issue

1

0 references

page(s)

15

0 references

copyright license

Creative Commons Attribution 2.0 Generic

3 references

Europe PubMed Central

17 September 2019

Europe PubMed Central

2 October 2019

Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis

Europe PubMed Central

27 September 2020

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Forest plots: trying to see the wood and the trees

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Bias in meta-analysis detected by a simple, graphical test

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Measuring inconsistency in meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Quantifying heterogeneity in a meta-analysis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Meta-analysis in clinical trials

19 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

19 March 2017

https://api.crossref.org/works/10.1186%2F1472-6904-11-15

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

22 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Varenicline: a first-line treatment option for smoking cessation

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Uncertainty in heterogeneity estimates in meta-analyses

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Rome III: the new criteria

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Regional, disease specific patterns of smoking-attributable mortality in 2000.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

The statistical basis of meta-analysis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Mortality from smoking worldwide.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-15

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-15

A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-15

Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-15

Varenicline for smoking cessation: a placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-15

In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-15

Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-15

Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3192741

Combination of log relative risk in retrospective studies of disease

29 November 2018

1 reference

12 December 2020

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation

1 reference

12 December 2020

Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up

1 reference

12 December 2020

The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial

1 reference

12 December 2020

The Combination of Estimates from Different Experiments

1 reference

https://api.crossref.org/works/10.1186%2F1472-6904-11-15

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1186/1472-6904-11-15

0 references